Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Empagliflozin
Drug ID BADD_D00765
Description Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.[A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.[L13688] The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects.[A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014.[A203501] As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold).
Indications and Usage Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Marketing Status Prescription
ATC Code A10BK03
DrugBank ID DB09038
KEGG ID D10459
MeSH ID C570240
PubChem ID 11949646
NDC Product Code 12714-201; 71796-001; 65727-085; 49629-033; 76072-1015; 0597-0152; 49629-034; 62756-159; 0597-0153; 55154-0412; 71610-177; 50090-4384; 59651-179; 50090-4492; 70518-2447; 46708-903; 42765-016; 67835-0024; 55154-0411; 69766-036; 69037-0029; 69766-052; 70518-1986
Synonyms empagliflozin | 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene | BI 10773 | BI10773 | BI-10773 | Jardiance
Chemical Information
Molecular Formula C23H27ClO7
CAS Registry Number 864070-44-0
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001--Not Available
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.003--
Abnormal dreams19.02.03.001; Available
Abscess11.01.08.0010.001123%Not Available
Acetonaemia14.01.01.0120.001123%Not Available
Acute hepatic failure09.01.03.001--Not Available
Acute myocardial infarction24.04.04.001; Available
Alanine aminotransferase increased13.03.01.003--
Alcohol abuse19.07.02.0070.001123%Not Available
Altered state of consciousness19.07.01.003; Available
Amylase increased13.05.01.0090.001123%
Anaphylactic reaction24.06.03.006;
Anaphylactic shock24.06.02.004; Available
Anger19.04.02.001--Not Available
Angina pectoris24.04.04.002;
Angina unstable24.04.04.004; Available
Angioedema23.04.01.001; Available
Anion gap increased13.02.01.0140.001123%Not Available
Anuria20.01.03.002--Not Available
Arrhythmia02.03.02.001--Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 17 Pages